In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Serenex Acquisition Adds Fuel to Heat Shock Fire

Executive Summary

Pfizer's acquisition of Hsp90 specialist Serenex is the biggest direct validation by Big Pharma in this up and coming oncology space. Hsp90, sometimes termed a master regulator, has quickly emerged as an important cancer target and Pfizer's endorsement can only give the field a boost.

Related Content

New Drugs Build On Personalized Medicine Momentum In Lung Cancer
Pfizer's Increasingly Specialist Focus
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2008
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008
Biopharma VC Exits 2005-2007: Cheap IPOs, Expensive Acquisitions
A New, Compelling Reason to Target Hsp90 in Tumor Cells
NovaCardia & Domain: New-Model Spec Pharma Investing
The $100 Million IND
The $100 Million IND
Serenex Inc.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts